EUVIMEDEUVIMED entdecken
Leserbrief

Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”

Eileen L Yoon, Jeong-Yeon Cho, Mimi Kim, Huiyul Park, Hye-Lin Kim, Dae Won Jun

Clinical and Molecular Hepatology · 06.11.2026

DOI: 10.3350/cmh.2026.0355 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 06.11.2026. Verfasst von Eileen L Yoon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We appreciate the careful reading and constructive critique, which provides us with an important opportunity to clarify the intended interpretation of our cost-effectiveness thresholds and to correct a typographical error in mapping of the currency conversion.First, regarding the concern about inconsistent logical operators (i.e., "AND" versus "OR") across sections and the apparent discordance between the narrative thresholds and Figure 3, we appreciate Wang's meticulous identification of these discrepancies.The intended interpretation of the two-way sensitivity analysis (Fig. 3) is that cost-effectiveness is determined by a joint interaction between the initial fibrosis regression gap and the minimum sustained durability, not by either parameter in isolation.As described in Figure 3, the relationship between these two parameters follows a trade-off frontier: a higher initial regression gap can compensate for a lower sustained durability, and vice versa.For example, a drug achieving an initial gap of over 10% with a sustained durability of 3% or higher was costeffective, as was a drug with a 15% or higher initial gap

Schlagwörter

Stichwörter der Autor:innen

Cost effectivenessFibrosisTreatment outcome

Autor:innen und Institutionen

  • Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
  • Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
  • Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA.
  • Department of Radiology, Hanyang University College of Medicine, Seoul, Korea.
  • Department of Family Medicine, Myoungji Hospital, Hanyang University College of Medicine, Goyang, Korea.
  • Department of Pharmacy, Sahmyook University College of Pharmacy, Seoul, Korea. maristella76@tistory.com.

Zitieren

APA

Yoon, E. L., Cho, J. Y., Kim, M., Park, H., Kim, H. L., & Jun, D. W. (2026). Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0355

Vancouver

Yoon EL, Cho JY, Kim M, Park H, Kim HL, Jun DW. Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0355

BibTeX
@article{Yoon2026,
  author = {Yoon, Eileen L and Cho, Jeong-Yeon and Kim, Mimi and Park, Huiyul and Kim, Hye-Lin and Jun, Dae Won},
  title = {Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2026.0355}
}
Kostenlos starten →